Charles has deep experience helping startups and Fortune 500 companies leverage data and analytics to drive insights and improve decision making. Charles is currently an Operating Partner at TO VC and on the Board of pioneering cancer company Kuva Labs. In prior roles, Charles focused on scaling world-class investment platforms, including Bridgewater Associates and Point72 Ventures, where he was COO. Previously, Charles launched the healthcare platform at Point72 Ventures, incubated a cancer imaging company, and co-created a life sciences tools platform now valued at $800M.
AtlasGEN Novel Drug Designer efficiently identifies new molecules based on favorable chemical properties and simultaneously evaluates them for clinical safety and effectiveness based on biology using VeriSIM Life’s groundbreaking Translational Index™ technology.
Iterative ranking of target engaging hits by their Translational Index values reduces the time and cost associated with other computational hit discovery approaches, while compressing the hit-to-lead refinement and optimization process by pre-validating hits for translatability. This unique integration dramatically reduces the number of compounds to evaluate in subsequent experimental research.
The ability to generate target engaging compound hits depends largely on the size of the molecular search library. The AtlasGEN search space is supported by more than 1 trillion compounds. Generative AI and deep learning techniques deliver unprecedented discovery capability.
AtlasGEN accurately predicts protein-lygand binding affinity by combining geometric conformer analysis with machine learning based on experimental data 72% more efficiently than molecular docking-based approaches.
.png)
